Literature DB >> 14986029

Relative expression of human telomerase catalytic subunit (hTERT) transcripts in astrocytic gliomas.

V Kotoula1, S Barbanis, E Nikolakaki, D Koufoyannis, C S Papadimitriou, G Karkavelas.   

Abstract

Human telomerase catalytic subunit (hTERT) expression has been reported as a marker for malignancy in various tumor systems. The aim of the present study was to investigate the relative expression of hTERT (relhTERT) and its transcripts A+B+ (contained in the full-length product), Adel and Bdel in astrocytic gliomas (grades I-IV, n=38). relhTERT was assessed by duplex reverse transcription-PCR and the expression profile of Adel, Bdel and A+B+ transcripts by nested real time-PCR. relhTERT and A+B+ presence correlated well with each other ( P<0.001) and with histological grading [grades I-II (low) vs III-IV (high), P(relhTERT)=0.002 and P(A+B+)<0.001]. A+B+ was detected in one out of seven hTERT-positive low-grade tumors, while it was present in 96.3%, and predominantly expressed in 59.3% of high-grade tumors. Bdel predominance was observed only in three cases, irrespective of grading, while Bdel levels equal or close to those of A+B+ were found in 30.4% of grade IV tumors. In situ hybridization with specific Bplus and Bdel probes revealed positive signals for both mRNAs in association with relhTERT and respective variant profiles. In addition, this method was useful in assessing hTERT expression in cases where sampling errors for RT-PCR were unavoidable. Our findings show that except for differences in relhTERT, low- and high-grade astrocytic gliomas exhibit distinct hTERT variant profiles, most of which seem to be in line with the role attributed to hTERT regarding its contribution to the acquisition of malignant potential during astrocyte carcinogenesis. Low-grade tumors mainly express Adel and Bdel. High-grade tumors, especially grade IV, always express A+B+, mostly but not always in predominance over Adel and Bdel. In this same group, profiles with Bdel predominance or relatively equal A+B+/Bdel expression are also observed, and Adel is often missing. Whether these differences characterize tumors with different biological behavior remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14986029     DOI: 10.1007/s00401-004-0832-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  6 in total

1.  The Clinical Implications of Human Telomerase Reverse Transcriptase Expression in Grade and Prognosis of Gliomas: a Systematic Review and Meta-analysis.

Authors:  Jing Li; Huiying Li; Jihong Liu; Bin Feng; Man Feng; Baoyu Lv; Shaomei Cheng; Xiangshan Yang
Journal:  Mol Neurobiol       Date:  2015-04-21       Impact factor: 5.590

2.  RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells.

Authors:  Ch Lavanya; M K Sibin; M M Srinivas Bharath; M Jeru Manoj; Manjunatha M Venkataswamy; Dhananjaya I Bhat; K V L Narasinga Rao; G K Chetan
Journal:  Cytotechnology       Date:  2016-10-18       Impact factor: 2.058

3.  Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics.

Authors:  Alma Ortiz-Plata; Martha Lilia Tena Suck; Mario López-Gómez; Alfonso Heras; Aurora Sánchez García
Journal:  J Neurooncol       Date:  2007-03-15       Impact factor: 4.130

4.  Alternative splicing and its impact as a cancer diagnostic marker.

Authors:  Yun-Ji Kim; Heui-Soo Kim
Journal:  Genomics Inform       Date:  2012-06-30

5.  mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (hTERT) in intracranial tumours of patients in the island of Crete.

Authors:  A Yannopoulos; E Dimitriadis; A Scorilas; T Trangas; E Markakis; M Talieri
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

Review 6.  Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy.

Authors:  Serena Bonomi; Stefania Gallo; Morena Catillo; Daniela Pignataro; Giuseppe Biamonti; Claudia Ghigna
Journal:  Int J Cell Biol       Date:  2013-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.